Bora Pharmaceuticals has announced the appointment of four business development directors to its commercial teams in the US and Taiwan.
Mark Dawson joins the team as Senior Director of Business Development. Based on the West Coast of the US in San Francisco, Dawson has CDMO sales experience, having worked for Catalent, Eurofins, and Patheon over the last decade.
Heading up the Southeast and Midwest sales in the US, David Scheib joins the team as a Business Development Director. Based in Georgia, Scheib brings almost 20 years of experience in pharmaceutical sales, having worked at Avara Pharmaceutical Services and Recro Pharma.
Responsible for the Northeast US and Eastern Canada, Bora has announced Kalyan Potluri as a Business Development Director. Formerly a Research Scientist at Pfizer before moving into sales for CDMOs such as Almac, Potluri’s background in R&D adds an understanding of drug development challenges to the team.
The company has appointed Wayne Hsiao as Asia Business Development Director. Hsiao brings over 17 years' sector experience, previously working in API business development and regulatory technical services at ScinoPharm. He will be responsible for advancing strategic partnerships across Asia.
Headquartered in Zhunan, Taiwan, Bora expects to complete the acquisition of GSK’s Mississauga, Canada facility by the end of 2020. The company will retain approximately 400 GSK staff and continue to produce GSK’s products for over 100 markets for a minimum of five years.
“We are excited about the addition of such an experienced business development team. The next six months will be an exceptional turning point for Bora as we complete the next phase of our expansion into North America with the acquisition of GSK’s world-class facility in Mississauga,” Sam Ricchezza, President of North America Operations said. “With the Mississauga manufacturing facility, we can leverage Canadian talent, capability, capacity, and location to become a truly global contract development and manufacturing organization.”